Top Stock Reports for NVIDIA, Abbott Laboratories & Linde
Thursday, May 8, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp. (NVDA), Abbott Laboratories (ABT) and Linde plc (LIN), as well as a micro-cap stock Tredegar Corp. (TG). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today's research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Jobless Claims, Q1 Productivity Hit Multi-Year LevelsToday's Featured Research ReportsNVIDIA's shares have outperformed the Zacks Semiconductor - General industry over the past year (+31.9% vs. +24.5%). The company is benefiting from the strong growth of artificial intelligence (AI), high-performance and accelerated computing. The growing demand for generative AI and large language models using graphic processing units (GPUs) based on NVIDIA's Hopper and Blackwell architectures is aiding data center revenues.Continued ramp-up of Ada RTX GPU workstations in the ProViz end market, following the normalization of channel inventory, is acting as a tailwind. The Zacks analyst expects NVIDIA's revenues to witness a CAGR of 27.7% through fiscal 2026-2028. Collaborations with over 320 automakers and tier-one suppliers are likely to advance its presence in the autonomous vehicles space.However, a limited supply of Blackwell and Ada GPUs could hinder its ability to meet demand. Rising costs associated with the production of more complex AI systems will hurt margins.(You can read the full research report on NVIDIA here >>>)Shares of Abbott Laboratories have outperformed the Zacks Medical - Products industry over the past year (+30.5% vs. +10.1%). The company's pipeline is unlocking new growth opportunities, supporting the company's positive momentum and strong growth outlook for 2025. Freestyle Libre, Lingo and Libre Rio CGM devices are on a great trajectory. Alinity, the company's next-generation suite of systems, is a key driver in the core lab diagnostics business.Abbott Laboratories is optimistic about its latest progress with biosimilars and expects this to significantly boost EPD sales, reportedly beginning this year. Despite softness in international pediatric arm, Abbott is regaining market share banking on strong Adult Nutrition business.Yet, the significant runoff of COVID-19 testing-related sales is hurting Abbott's Diagnostics growth. Headwinds such as tough macro conditions and foreign exchange also add to the worry.(You can read the full research report on Abbott Laboratories here >>>)Linde's shares have outperformed the Zacks Chemical - Specialty industry over the past year (+5.9% vs. -2.5%). The company remains a dominant player in the industrial gas sector, delivering strong financial performance with consistent EPS growth, disciplined capital allocation, and industry-leading margins.Linde's record $10 billion backlog ensures long-term revenue stability, while sustainability initiatives position it as a leader in low-carbon energy solutions. Strategic investments in high-return projects and small on-site contracts further reinforce its competitive edge.However, foreign exchange headwinds, softening industrial demand in Europe & China, and regulatory uncertainties pose challenges. Also, slower growth in healthcare impacts diversification efforts. Despite these risks, LIN's strong execution, efficiency improvements, & long-term contracts position it well for sustained profitability & resilience in fluctuating market conditions.
(You can read the full research report on Linde here >>>)Shares of Tredegar have outperformed the Zacks Chemical - Plastic industry over the past year (+30.5% vs. +10.1%). This microcap company with market capitalization of $282.47 million have $78 million Terphane divestiture in Nov 2024, plus $7 million due by Mar 2025, which lowered net leverage from 2.3X to 1.2X, bolstering financial flexibility for debt reduction and reinvestment.Surface Protection rebounded with 57% volume growth and $19.4M EBITDA gain. The Obsidian film launch in October 2024 marks a strategic entry into automotive displays, expanding high-margin revenue. Despite a $13.3 million impairment at Clearfield, Aluminum Extrusions' EBITDA rose $3.4 million, with diverse end-markets buffering cyclicality. Gross margin improved to 16.1% on operational gains.However, risks persist, such as cyclical exposure in non-residential construction and auto sectors weighing on visibility; PE Films faces customer concentration and tech disruption risks; regulatory compliance burdens could stress cash flows.(You can read the full research report on Tredegar here >>>)Other noteworthy reports we are featuring today include Citigroup Inc. (C), CME Group Inc. (CME) and Constellation Energy Corp. (CEG).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
NVIDIA (NVDA) Rides on Strong Adoption of GPUs, Partnerships
Abbott (ABT) EPD Gains in Emerging Space on Branded Generics
Linde's (LIN) Long-Term Contracts With Minimum Volume Aid
Featured Reports
Citigroup's (C) Streamlining Efforts Aid Amid Rising CostsThe Zacks analyst views Citigroup's efforts to grow core businesses by streamlining operations as impressive. Yet, revamping technology and risk management frameworks might flare up Costs.
Focus on Renewable Energy Aid Constellation Energy (CEG)Per the Zacks analyst, Constellation Energy gains from expansion of renewable portfolio. Its position as an industry leader in the safe operation of nuclear plants helps it increase its nuclear output
Solid Expansion Projects to Aid Teck (TECK) Amid High CostsPer the Zacks analyst, Teck Resources is poised well to gain from its solid expansion project pipeline despite cost pressures.
Trimble (TRMB) Benefits from Strong Recurring Revenue GrowthPer the Zacks analyst, Trimble benefits from strong growth in its recurring revenue streams, particularly in its AECO and Field Systems segments.
Leasing Aids Regency Centers (REG) Amid E-Commerce AdoptionPer the Zacks Analyst, Regency Centers is to gain from healthy leasing activity aiding occupancy and rent growth, key investments and a focus on essential retail assets. Yet, e-commerce adoption ails.
Ensign Group's (ENSG) Strategic Buyouts Aid Amid High CostsPer the Zacks analyst, Ensign Group's expertise in acquiring healthcare-related real estate and transforming them into market leaders are commendable. Yet, rising costs weigh on margins.
Investments & Expanding Customer Base Aid ONE Gas (OGS)Per the Zacks analyst, ONE Gas' capital expenditure should improve pipeline integrity and boost its performance. Rising demand from an expanding customer base should further boost the top line.
New Upgrades
Improving Clearing and Transaction Fees Aid CME Group (CME)Per the Zacks analyst, CME Group is set to grow on higher clearing and transaction fees as market position, diverse derivative product lines and expansion of futures products drive volumes.
Bandwidth (BAND) Rides on Solid Demand, Strategic CollaborationPer the Zacks analyst, healthy traction for Bandwidth's communication services in multiple sectors such as healthcare, IT services, retail and fintech will likely drive its top line.
AngioDynamics (ANGO) Rises on NanoKnife, Product StrengthPer the Zacks Analyst, AngioDynamics' strong NanoKnife momentum, deep focus on the pancreatic cancer market, and an expanding, robust product pipeline position it well for sustained long-term growth.
New Downgrades
Economic Uncertainty & High Labor Costs Hit Allegiant (ALGT)The Zacks analyst is worried about the high labor costs at Allegiant. High costs are hurting the bottom line. Tariff-induced uncertainty adds to its woes.
Macroeconomic Pressures to Hurt Carter's (CRI) Top LinePer the Zacks analysts, inflation, elevated interest rates and weakening consumer confidence are likely to hurt Carter's top line. The company is seeing reduced demand across segments.
Dismal Contract Sales Hurt Marriott Vacations (VAC) ProspectsPer the Zacks analyst, Marriott Vacations operations are likely to be hurt by dismal contract sales and fall in VPG. Also, an uncertain macro environment and elevated expenses are a headwind.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Citigroup Inc. (C) : Free Stock Analysis Report
Abbott Laboratories (ABT) : Free Stock Analysis Report
CME Group Inc. (CME) : Free Stock Analysis Report
Constellation Energy Corporation (CEG) : Free Stock Analysis Report
NVIDIA Corporation (NVDA) : Free Stock Analysis Report
Tredegar Corporation (TG) : Free Stock Analysis Report
Linde PLC (LIN) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
36 minutes ago
- Bloomberg
Meta in Talks for Scale AI Multi-Billion Investment
Live on Bloomberg TV CC-Transcript 00:00Not exactly a household name. What do scale AI do. And how significant is the investment? Yeah, absolutely. Few people have heard outside of the world of technology and of course of this company, but it has grown in prominence. And now, of course, it's making headlines with this potential investment, 0 billion from META, as you say, one of the biggest private sector investments that we would have seen for years. So Scale AI it focuses on one of the three key components that you need to build out large language models, which is data. So you have energy chips and data, though those are the three main components that come together. And scale AI is squarely focused on data. So they train up, or at least they build out quality data that these models then feed in to train on and they hire PhDs and others to help work through that data and quantify it and tag it. So that's essentially the business model. They've also providing their own solutions into enterprise and have been pushing into defence as well. And I think what this deal tells us is a few things. One Meta of course, that Mark Zuckerberg is not going anywhere in terms of its investments around A.I.. They've pledged to invest at least $60 billion this year and 10 billion now for scale A.I.. If this, of course, comes to pass, so Meta is full bore on the focus on AI, particularly as well around data, it's a reminder that data is becoming a key battleground because along with energy and chips getting hold of the data, quality data is becoming increasingly difficult for these large language models. And so there is a fight on that spectrum as well. And then the third part of this, I think, in terms of what it tells us is defence technology Meta is increasingly working with the Pentagon, particularly further around things like virtual helmets and AI infused helmets for the military. And scale AI already has relationships with the Pentagon. So I think it's also a reminder that matter is getting closer in terms of defence technology as well. So on all three levels, I think those are the significance In terms of the deals that came through this company. Scale AI was valued at 14 billion USD back in 2024. You can imagine that that valuation is much higher now. Yeah. And also we've got London Tech Week kicking off today. What's the top of the agenda? Well, I was talking about data and energy and chips while chips will be front and center because Jensen Huang of nvidia will be giving the keynote speech at London Tech week later this morning alongside the Prime Minister Keir Starmer. Nvidia also expected to announce Jensen Huang some investments here in the UK around training the workforce to be able to use these A.I. applications. They've pledged to train about 100,000 people up until about 2030, investing in the R & D space as well in Bristol, Bristol here in the UK. So the focus is going to be on Jensen Huang has to say at that keynote speech and those investments and how the UK is trying to position itself in this AI race versus the US versus China and also as well versus their counterparts across the channel in Paris because France is also hosting Viva Tech, which is a big tech event and Jensen Huang will be going there as well. And France has been able to build out an AI ecosystem with tax cuts. That is something that arguably the UK government be looking for, which is desperate for growth. And there is one solution for this UK government. They hope to drive growth levels higher in the UK.
Medscape
38 minutes ago
- Medscape
AI Scribes Cutting GPs' Admin and Boosting Patient Care
Artificial intelligence (AI) scribing tools are increasingly being used in NHS settings to enhance patient care and free up staff time. In April, the Department of Health and Social Care announced support for NHS doctors to adopt AI tools that 'bulldoze bureaucracy,' allowing clinicians to focus more on their patients and less on documentation. This follows a multi-site evaluation led by Great Ormond Street Hospital for Children, London, England, and funded by NHS England. The trial tested ambient voice technologies (AVTs) that listen to and transcribe consultations in real time. More than 7000 patients took part across settings including accident and emergency, primary care, community services, and mental health. Interim data from the trial showed increased productivity and more time spent on direct care, particularly in emergency settings. Current AI Scribing Tools in Use Several AI scribing tools are already being used within the NHS. Health technology company Accurx recently teamed up with Tandem Health to launch Accurx Scribe, a tool that can transcribe, summarise, and code patient consultations into a trust's clinical records, with functionality to write back to EMIS and SystmOne. It is currently being rolled out across GP practices using Accurx. At the Royal Wolverhampton NHS Trust, a pilot of CLEARNotes is underway. The tool listens to patient consultations and generates a structured summary of the discussion. Meanwhile, Heidi Health is being used by about 40% of GPs and is being piloted in 15 NHS trusts. The AVT tool provides real-time transcription, without storing audio files, in order to address patients' privacy concerns. GP Practices See Significant Benefits At Modality, a group of general practices in West Yorkshire, Heidi has been installed for all GPs and advanced clinical practitioners. Tom Ratcliffe, a GP partner and digital transformation clinical lead for the group, said: 'Clinicians find that it saves time and reduces their administrative burden, particularly around generating clinical correspondence after consultations.' Tom Ratcliffe Ratcliffe described using an AI scribing tool as 'quite transformative' and particularly beneficial for clinicians who are slower typists or who take longer to write detailed notes. 'One of the really significant benefits we've experienced is that by having an ambient scribe writing the notes while you're speaking with a patient, it enables you to focus more on them,' he told Medscape News UK . 'That's really important, as you're then picking up on non-verbal cues that you can easily miss when you're distracted by the computer.' With GPs having between 30 and 50 clinical contacts per day, 'having to think about exactly what to write for each of those encounters is quite a drain on your mental capacity,' Ratcliffe said. 'My colleagues and I have all found using an ambient scribe helps to reduce your cognitive load. Having a consistent format for the notes for every encounter is also helpful,' he added. Patient Consent and Data Security Educating patients about the software is an important consideration. Thomas Kelly, co-founder and chief executive of Heidi Health, said clinicians are advised to obtain consent before using the tool and to explain to patients how an AI scribe works and what they can expect during a consultation. Thomas Kelly 'Patients can also learn more through a range of resources that GPs can put up in their practices that explain how Heidi works,' Kelly said. A transcription of the consultation will be generated, 'but the audio is not permanently recorded or stored in a way that could ever be breached,' he explained. 'It's just being turned into that documentation in real time, and this process is happening on Heidi's servers in the UK.' However, when a session is deleted from Heidi's servers, 'it's deleted for everyone, and there is no way it can be retrieved.' Ratcliffe said that patients have reacted positively to their Modality GP using an AI scribing tool. 'With all the digital innovations we've introduced, we've always had patients who raised very reasonable questions about the privacy of their data,' he said. 'But the level of patient acceptance of using Heidi has been incredibly high.' Each patient is asked to give their consent for the scribing tool to be used. 'I haven't heard of a single example of a patient declining use in an encounter, and we've done probably hundreds or thousands of these now,' said Ratcliffe. Accuracy Concerns Addressed Andrew Noble works within the frailty service at Jean Bishop Integrated Care Centre in East Hull, England. He uses Heidi for consultations lasting up to an hour, which require lengthy administration time. Andrew Noble Staff training on the system emphasises vigilance about possible AI hallucinations in output. According to Noble, one or two minor errors might occur during an hour-long consultation transcription. However, for shorter appointments, lasting 15 minutes, clinicians might expect error-free note-taking from the AI scribe. Use of the tool has significantly improved the quality of note-taking. 'The Heidi AI scribe halved the number of spelling mistakes, and it reduced the number of abbreviations quite significantly as well,' said Noble. Mistakes might include US spellings of antibiotics or the scribe mishearing the name of a medication. 'But we do have human error when inputting our own notes, so those things were already happening from time to time,' Noble observed. Ratcliffe tested multiple AI scribe options before selecting Heidi Health. All platforms occasionally made minor errors. 'Anyone who uses any form of generative AI does find it will occasionally confabulate or hallucinate,' he said. 'One of the key parts of our training was around educating clinicians on the importance of understanding that their role has gone from spending lots of time typing up notes to carefully reading a transcript and checking for any potential issues.' Overall, 'we haven't found that the error rate is high enough that means it's unsafe or not practical to use,' said Ratcliffe. Game-Changing Technology? Health Secretary Wes Streeting has described AI as a catalyst that will revolutionise healthcare. GPs appear to share this optimism. 'This was something that we worked really hard to roll out quickly because we did feel that it was game-changing,' Ratcliffe explained. 'I think it has been game-changing for a lot of our clinicians. When used properly, it can make a big difference.' With GPs working 'above and beyond,' Ratcliffe believes that AI scribing tools 'could help us to move back to a safer place in terms of making our workload more manageable.'
Tom's Guide
44 minutes ago
- Tom's Guide
I played 1,000 hours on Nvidia RTX 5070 Ti – here's why it's the MVP (if you don't overpay)
I've played games on Nvidia's entire RTX 50-series lineup, and out of all of them, the RTX 5070 Ti is the sweet spot – high-enough specs, enough pure rendering horsepower and the right amount of DLSS 4 AI trickery to be the best of all worlds at all resolutions to all players. That is providing you buy it at the recommended retail price. In the U.K., this is not a problem. You can snag one right now at £10 below MSRP right now from Overclockers, as stock has finally normalized. But the U.S. is still in a bit of a tight spot at the moment with prices in excess of $100 over that $749 MSRP. That's not to say you're getting a bad GPU. In fact, this is the best of Nvidia's current generation – unlocking enough of what Blackwell architecture can do with 16GB of GDDR7 video memory on a much faster 256-bit bus, and a strong increase in AI tensor cores and rendering CUDA cores. All of that means a real leap over the RTX 5070 that leaves it in the dust, and a real high-end feel to everything over the RTX 5060 Ti, and even gives the RTX 5080 a run for its money. This is the MVP in terms of giving you esports-tier blazing frame rates at up to 1440p, with silky smoothness capable with DLSS at everything turned up to max. Plus, this all adds to this being an AI and content creation workload monster too. But you all know the RTX 50-series script by now. If you don't, let me break it down: Got it? Good. Now let me tell you about my time with it. For frame of reference, we are using some testing data from our friends over at Tom's Hardware. If you're looking for more dense detail and analysis on specific cards, our sister site is the best place to go! RTX 5070 Ti RTX 4070 Ti Super Price (MSRP) $749 $799 Video memory 16GB GDDR7 16GB GDDR6X RT Cores 70 4th Gen cores 66 3rd Gen cores Tensor Cores 280 5th Gen cores 264 4th Gen cores CUDA Cores 8,960 8,448 Power consumption (TDP) 300W 285W Ports 1x HDMI 2.1b, 3x DisplayPort 2.1b 1x HDMI 2.1, 3x DisplayPort 1.4a Housed in the elegant Fractal North chassis, this powerhouse build features AMD's Ryzen 7 9800X3D processor, paired with 32GB of high-speed Corsair DDR5 memory and the blazing-fast WD_Black SN8100 PCIe Gen 5 SSD from SanDisk. Power is delivered by a robust 850W Corsair PSU, while all components are anchored to the Asus TUF Gaming B850-Plus motherboard with built-in Wi-Fi 7. Keeping temperatures in check and performance consistent is the FrostFlow 200 Series cooler, ensuring no thermal throttling under load. The MSRP may not be holding Stateside, but that doesn't stop the RTX 5070 Ti really shining as the mid-range beacon of a desktop gaming GPU. For raw rendering, the RTX 5070 Ti stands up as a fantastic GPU for getting blistering esports-level frame rates at 1080p, and looking incredible at 1440p. For 4K, you can get some solid 60+ FPS in certain well-optimized games, but that's where DLSS will come in (more on that later). GPU Cyberpunk 2077 ray tracing ultra 1440p Forza Horizon 5 max settings 1440p RTX 5070 Ti 53 FPS 196 FPS RTX 4070 Ti Super 52.6 FPS 126 FPS RTX 5070 41 FPS 171 FPS RX 9070 XT 47.3 FPS n/a RX 9070 39.6 FPS n/a RTX 5060 Ti 30 FPS 121 FPS Once again, it's worth prefacing this by saying that the gap between this and the last generation is still within that 5-15% range that wouldn't make this a smart buy over sticking with your RTX 4070 Ti Super. But to those on older GPUs or gaming enthusiasts looking for some real future-proofing, these are encouraging numbers. Flick on the AI magic with DLSS 4 and multi-frame generation, and your frame rates take off like they just downed an energy drink — turbocharged and leaving your old numbers in the dust. You already know how Nvidia's AI trickery works here – moving from the convolutional neural network of DLSS 3 to work more like ChatGPT with a transformer model that is more accurate at analyzing scenes on the fly to smoothen frame rates. The end result is barely noticeable ghosting around textures and significantly faster frame rates that don't bring on much latency. This is always a concern as Nvidia crams AI generated frames between rendered frames, which doesn't equate to making something feel more responsive to play. But whether it's zippy multiplayer games that require twitch reactions or more slower-paced single-player adventures, there were no issues with latency with Reflex and strong rasterization. You can really notice a marked difference in GPU-intensive tasks like editing multiple layers of 4K video in Davinci Resolve or running on-device AI neural edits in Photoshop. Plus with support for the 4:2:2 color format, you gain access to a vastly more efficient format, which provides better flexibility and fidelity in all your grading. Blender is the key way to detect whether your GPU is going to be good at advanced content creation and animation, and these incredibly encouraging numbers are reflective of the experience you get. Most tasks go by in a flash and nothing feels insurmountable. I always know that Nvidia is always going to have a leg up on the competition, being the AI company it is now and all. But by this point, it's kind of funny to see how far ahead its consumer GPUs are in AI performance – not just improving game performance, but running AI-fueled tasks at the speed of light, running image generation and even running local LLMs. That's not to say the sweet spot doesn't come with some hitches on the way for the RTX 5070 Ti. For my fellow Brits, it's good news. The RTX 5070 Ti is readily available at the recommended retail price with little to no increases. In fact, the only price rises you'll see is on brands who have gone OP with the cooling methods to allow for overclocking. However, stock is slim in the U.S. and that is leading to some tough-to-swallow price rises. At a minimum, you could be paying $30 more, but it's looking more like an average of a $85 scalp across all the retailers I've seen. If you can wait, please do so! The RTX 5070 Ti is the sleeping giant of Nvidia's RTX 50-series lineup – the one that is ideal for those of you who want the versatility to get great performance across all your games and GPU-intensive workloads without breaking the bank. But 'breaking the bank' continues to be a problem in the U.S., as MSRP seems to be a distant myth right now. Nvidia has told us that RTX 5070 Ti stock should be increasing with faster production times, but whether this will normalize the price, we'll just have to wait and see. For my fellow Brits, this isn't a problem, and I recommend you buy now as you can get them at bang on (or slightly under) the recommended price. But to my mates in the States, hold your nerve for those prices to come down on one of the best GPUs you can buy right now.
